Aptevo Therapeutics, Inc. (APVO)
1.87
-0.01
(-0.53%)
USD |
NASDAQ |
Sep 09, 16:00
1.87
0.00 (0.00%)
After-Hours: 16:08
Aptevo Therapeutics Debt to Equity Ratio : 0.6967 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.6967 |
| March 31, 2026 | 0.3808 |
| December 31, 2025 | 0.2663 |
| September 30, 2025 | 0.2294 |
| June 30, 2025 | 0.6452 |
| March 31, 2025 | -3.002 |
| December 31, 2024 | 0.9735 |
| September 30, 2024 | 1.093 |
| June 30, 2024 | 1.126 |
| March 31, 2024 | 0.8543 |
| December 31, 2023 | 0.4416 |
| September 30, 2023 | 0.3788 |
| June 30, 2023 | 0.3537 |
| March 31, 2023 | 0.2544 |
| December 31, 2022 | 0.5949 |
| September 30, 2022 | 0.6438 |
| June 30, 2022 | 0.4664 |
| March 31, 2022 | -7.568 |
| December 31, 2021 | 37.97 |
| September 30, 2021 | 6.702 |
| June 30, 2021 | 3.617 |
| Date | Value |
|---|---|
| March 31, 2021 | 4.838 |
| December 31, 2020 | 1.689 |
| September 30, 2020 | 12.63 |
| June 30, 2020 | 0.3303 |
| March 31, 2020 | 0.2045 |
| December 31, 2019 | 1.958 |
| September 30, 2019 | 1.226 |
| June 30, 2019 | 0.9306 |
| March 31, 2019 | 0.6161 |
| December 31, 2018 | 0.634 |
| September 30, 2018 | 0.4351 |
| June 30, 2018 | 0.3492 |
| March 31, 2018 | 0.2824 |
| December 31, 2017 | 0.2324 |
| September 30, 2017 | 0.1936 |
| June 30, 2017 | 0.3645 |
| March 31, 2017 | 0.2998 |
| December 31, 2016 | 0.3635 |
| September 30, 2016 | 0.2841 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 14.52M |
| Total Liabilities (Quarterly) | 8.478M |
| Shareholders Equity (Quarterly) | 6.041M |
| Current Ratio | 2.081 |
| Net Debt Paydown Yield | 0.68% |